EUVIMEDAtrasti EUVIMED
Fallbericht

Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up

Michinori Funato, Atsunari Kino, Reina Iwata, Misaki Yumioka, Kohei Yamashita, Chika Urui, Ryoya Uno, Emi Kondo, Etsuko Morioka, Yoko Ogawa, Akihisa Kawamura, Toshifumi Kusukawa and 1 more

Brain and Development · 2024

DOI: 10.1016/j.braindev.2023.08.005 ↗

At a glance

Fallbericht in Brain and Development, 2024. Written by Michinori Funato and 12 co-authors. Institution: Department of Pediatric Neurology, National Hospital Organization Nagara Medical Center, Gifu, Japan. Electronic address: mfunato@mac.com. Major MEDLINE topics: Muscular Atrophy, Spinal, Spinal Muscular Atrophies of Childhood. Cited 3 times so far (Crossref); 23 references. Funded by: Japan Society for the Promotion of Science.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

BACKGROUND: Spinal muscular atrophy (SMA) is a hereditary neuromuscular disorder characterized by skeletal muscle atrophy and weakness. New treatments for SMA have been developed namely, the drugs nusinersen, onasemnogene abeparvovec, and risdiplam. However, there are limited reports on their effects on adult patients with SMA, particularly over long periods. Therefore, this study aimed to determine the efficacy of nusinersen treatment in adult patients with SMA. METHODS: We retrospectively reviewed patients with SMA type 2 or 3 who received nusinersen treatment between January 2018 and January 2023. All patients were evaluated using the Hammersmith Functional Motor Scale-Expanded (HFMSE) before the commencement of nusinersen treatment, and the change with respect to the baseline HFMSE score was compared. RESULTS: A total of six patients, three patients each with SMA type 2 or 3, were treated with nusinersen. The median age of the patients before the commencement of nusinersen treatment was 51.5 years (range, 33-59 years), and the median treatment period was 50.5 months (range, 33-57 months). Three patients showed an increased tendency of improvement on the HFMSE at 15-26 months after nusinersen treatment, and the HFMSE score was maintained in two patients. Significant adverse events were observed in three patients: one subdural hematoma, one incidental bone fracture, and one cheek dermatofibrosarcoma. CONCLUSIONS: Nusinersen treatment showed later efficacy in adult patients with SMA type 2 or 3. The distinct efficacy of nusinersen requires further investigation using a large number of cases and a long follow-up period.

Subjects

MeSH terms (MEDLINE)

Muscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodAdultHumansMiddle AgedRetrospective StudiesFollow-Up StudiesOligonucleotides

Author keywords

Adult patientsHammersmith Functional Motor Scale-ExpandedLater efficacyNusinersenSpinal muscular atrophy

Substances

nusinersenOligonucleotides

Authors and institutions

  • Department of Pediatric Neurology, National Hospital Organization Nagara Medical Center, Gifu, Japan. Electronic address: mfunato@mac.com.
  • Department of Anesthesia, National Hospital Organization Nagara Medical Center, Gifu, Japan.
  • Department of Pharmacy, National Hospital Organization Nagara Medical Center, Gifu, Japan.
  • Department of Rehabilitation, National Hospital Organization Nagara Medical Center, Gifu, Japan.
  • Department of Pediatric Surgery, National Hospital Organization Nagara Medical Center, Gifu, Japan.

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Funato, M., Kino, A., Iwata, R., Yumioka, M., Yamashita, K., Urui, C., Uno, R., Kondo, E., Morioka, E., Ogawa, Y., Kawamura, A., Kusukawa, T., & Minatsu, H. (2024). Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up. Brain and Development. https://doi.org/10.1016/j.braindev.2023.08.005

Vancouver

Funato M, Kino A, Iwata R, Yumioka M, Yamashita K, Urui C, et al. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up. Brain and Development. 2024. doi:10.1016/j.braindev.2023.08.005

BibTeX
@article{Funato2024,
  author = {Funato, Michinori and Kino, Atsunari and Iwata, Reina and Yumioka, Misaki and Yamashita, Kohei and Urui, Chika and Uno, Ryoya and Kondo, Emi and Morioka, Etsuko and Ogawa, Yoko and Kawamura, Akihisa and Kusukawa, Toshifumi and Minatsu, Hiroshi},
  title = {Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up},
  journal = {Brain and Development},
  year = {2024},
  doi = {10.1016/j.braindev.2023.08.005}
}
Start for free →